Pharma BD Deal Intelligence
Back-loaded AI-discovery collaboration in hard-to-drug neuroimmune CNS
Full analysis, sources & comparables →SK Biopharmaceuticals and Insilico Medicine formed an AI-powered drug discovery collaboration, announced at the BIO 2026 International Convention, to discover novel candidates for neuroimmune CNS disorders using Insilico's generative AI platform. Insilico receives ~$18M in near-term payments and is eligible for up to $2.5 billion in milestones plus single-digit royalties; SK Biopharmaceuticals leads subsequent development and commercialization. It is Insilico's largest APAC partnership by potential value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| SK Biopharmaceuticals Co., Ltd. / Insilico Medicine Inc. (this deal) | 2026 | $2.5B | 48 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals